Navigation Links
Surefire Medical Launches Next Generation Infusion System ST-LT and Specialty Catheters at SIR - Maximizing Targeted Delivery of Embolics Without Reflux

New Orleans, LA (PRWEB) April 13, 2013

Surefire Medical, Inc., the developer of a new class of infusion systems designed to maximize targeted delivery of embolization agents without reflux, today announced the launch of the company’s next-generation Surefire Infusion System and Specialty Catheters at the Society of Interventional Radiology (SIR) 38th Annual Meeting, held in New Orleans April 13-18. The new ST and LT microcatheters can accommodate smaller vessels and selective procedures in direct-to-tumor cancer treatment.

Now available in the U.S., Europe, Canada and New Zealand, the company’s new Surefire Infusion System--ST and Surefire Infusion System--LT microcatheters for the interventional radiology and interventional oncology markets are distinguished by their expandable tip. When deployed, the tip expands dynamically to the walls of the artery, preventing any damage caused by backflow into healthy, non-target vessels and tissues.

“The new Surefire Infusion System makes some treatment dilemmas far less problematic, and thus may improve patient safety. However, the far more exciting aspect of the new system is the potential for improving the efficacy of therapy, said Fred Moeslein, M.D., Interim Director, Division of Vascular and Interventional Radiology, University of Maryland School of Medicine.

“Currently, Drug-Eluting Bead Chemoembolization (DEB-TACE) is performed routinely across this country and around the globe using end-hole catheters. Often, especially in the setting of hypovascular tumors or heavily pretreated tumors, stasis is reached early, thus limiting drug delivery. The Surefire system allows us to deliver more drug to the tumor, even in the setting of stasis without risk of reflux or non-target embolization. Therefore the new system gives us the capability to control drug delivery far better than with a standard end-hole catheter.”

In addition, newly published data in the Journal of Vascular and Interventional Radiology show Surefire’s technology significantly increases penetration of embolic agents at the targeted cancer site, to 99.9 percent compared to 72.8 percent when using end-hole catheters.

The Surefire Infusion System--ST for vessels from 3mm to 4.5 mm in size, and the Surefire Infusion--LT for larger vessels from 4 mm to 6 mm in size, are used in diagnostic and therapeutic procedures to deliver radiopaque media and embolization agents to selected sites in the peripheral vascular system.

Surefire’s New Specialty Catheters
Also introduced today are Surefire’s Specialty Catheters, the Simmons 1 and Axis, available in a variety of different curve styles for accessing the wide range of patient anatomies.

“Surefire’s ST and LT microcatheters and Specialty Catheters are rapidly proving to better meet clinical needs in targeted delivery of embolics,” said Surefire CEO and President Jim Chomas.

The Surefire Infusion System-ST, LT and Specialty Catheters have received regulatory approval in the U.S., Europe, and New Zealand.

SIR Booth Speaker Schedule
The following experts will discuss new techniques made possible by the Surefire Infusion System ST-LT at Surefire Medical booth #1847:

  •     Sunday, April 14, 2013 • 3:00 pm - 3:30 pm
Aravind Arepally, MD: Bronchial Artery Embolization to Protect the Anterior Spinal Artery

  •     Monday, April 15, 2013 • 9:30 am - 10:00 am
Charles Nutting, DO: The Use of the Surefire Infusion System in Aberrant Vascular Anatomy

  •     Monday, April 15, 2013 • 3:00 pm - 3:30 pm
Steve Rose, MD: The Hemodynamics of the Surefire Infusion System

  •     Tuesday, April 16, 2013 • 9:30 am - 10:00 am
Aaron Fischman, MD: The Use of the Surefire Infusion System with Transradial Access

  •     Tuesday, April 16, 2013 • 3:00 pm - 3:30 pm
Bud Liddell, MD: Improved Targeted Delivery with Drug-Eluting Beads

About Surefire Medical
Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue. For more information, please visit
                # # # #

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. AtheroNova Adds New Medical Advisor
2. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
3. “Scientific And Medical Research On The Successful Treatment Of Type 1 + 2 Diabetes With Alkaline Reduced Water” is Reviewed in Today’s Bawell Water Ionizer Health Report
4. Dermatology Associates Medical Group in Beverly Hills Announces Safe, Fast Anti-Aging Laser Treatment
5. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
6. Medical Marijuana Inc., Corporate Update- Significant Revenue and Net Income Growth 1st Quarter- Division and Corporate Holdings Update
7. First Warning Systems, Inc., Appoints Veteran Medical Executive Royea as CEO
8. Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
9. Medical University of South Carolina Selects Elseviers Interdisciplinary Care Planning and Clinical Documentation Solution
10. Final Week of IpAuctions, Inc. All Things Medical Auction Event
11. Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
Post Your Comments:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):